Isolation and Evaluation of Clinically Important Acinetobacter Baumannii From Intensive Care Unit Samples

Mohamed Mowfik Sehree; Hanaa N. Abdullah; Amani M. Jasim

doi:10.51173/jt.v3i3.324

Authors

Mohamed Mowfik Sehree College of Nursing, University of Telafer, Iraq
Hanaa N. Abdullah College of Health and Medical Technology, Middle Technical University, Baghdad, Iraq
Amani M. Jasim College of Health and Medical Technology, Middle Technical University, Baghdad, Iraq

DOI:

https://doi.org/10.51173/jt.v3i3.324

Keywords:

Acinetobacter baumannii, VITEK-2, Antibiotic susceptibility, Intensive Care Unit

Abstract

Acinetobacter baumannii is considered a critical healthcare problem for patients in intensive care units due to its high ability to be multidrug-resistant to most commercially available antibiotics. The current study is at aimed at isolating and identifying the clinical isolates of A. baumannii from different samples and investigating the antibiotic resistance of isolates. Isolation and diagnosis of bacteria were achieved by conventional techniques, including routine and selective culture media (Chrome agar), biochemical test, EPI 20E, and VITEK-2. These methods were basically considered as a gold standard for identification of A. baumannii infections from different clinical sources, and culture positive isolates were tested for antibiotic susceptibility using a modified Kirby–Bauer method. A total of 375 clinical specimens were collected from different infections in some hospitals in Mosul and Erbil cities/Iraq from Sep 2020 to Jan 2021. Overall, 41 isolates were identified as A. baumannii using conventional and biochemical methods, and then confirmed by VITEK-2 system. Our results established that only 41(14.4%) isolates were diagnosed as A. baumannii, and most of these isolates were from burns (36.5%), surgical wounds (34.1%), and sputum (14.6%). However, it was identified in CSF, blood, and urine samples with lower percentages (7.3%, 4.8%, and 2.4%, respectively). The clinical isolates of A. baumannii showed high to moderate resistance to Piperacillin (97.5%), Piperacillin/ Tazobactam., Ceftazidime (87.8%), Meropenem (85.3%), Tri/slphamethoxazole (82.9%), Levofloxacin (80.4%), Imipenem, Ciprofloxacin (78%), Gentamycin (75.6%), Amikacin (73.1%), Netilmicin (68.2%), Tobramycin (60.9%) and Tetracycline (31.7%). However, two antimicrobial agents which were Colistin and Tigecycline produced 0 and 2.4 % resistance to A. baumannii respectively, which were considered the most used choices to treat A. baumannii infections.

The current findings suggest that automated Vitek 2 system is the most common method to accurately detect the isolates and evaluate multi-drug resistant A. baumannii among patients.

Downloads

Download data is not yet available.

References

M. Nguyen and S. G. Joshi, “Carbapenem resistance in Acinetobacter baumannii, and their importance in hospital-acquired infections: a scientific review,” J. Appl. Microbiol., pp. 1–24, 2021, doi: 10.1111/jam.15130.

M. Singhai, A. Malik, M. Shahid, M. A. Malik, and R. Goyal, “A study on device-related infections with special reference to biofilm production and antibiotic resistance,” J. Glob. Infect. Dis., vol. 4, no. 4, pp. 193–198, 2012, doi: 10.4103/0974-777X.103896.

E. Dahdouh, “Epidemiological and Molecular Analysis of Virulence and Antibiotic Resistance in Acinetobacter baumannii,” 2017.

P. A. Hassan and A. K. Khider, “Correlation of biofilm formation and antibiotic resistance among clinical and soil isolates of acinetobacter baumannii in Iraq,” Acta Microbiol. Immunol. Hung., vol. 67, no. 3, pp. 161–170, 2020, doi: 10.1556/030.66.2019.026.

A. F. G. Ravea, A. V. Kussb, G. H. S. Peila, S. R. Ladeirac, J. P. V. Villarreald, and P. S. Nascentee, “Biochemical identification techniques and antibiotic susceptibility profile of lipolytic ambiental bacteria from effluents,” Brazilian J. Biol., vol. 79, no. 4, pp. 555–565, 2019, doi: 10.1590/1519-6984.05616.

A. Hassan, J. Usman, F. Kaleem, M. Omair, A. Khalid, and M. Iqbal, “Evaluation of different detection methods of biofilm formation in the clinical isolates,” Brazilian J. Infect. Dis., vol. 15, no. 4, pp. 305–311, 2011, doi: 10.1016/s1413-8670(11)70197-0.

P. S. Gellings, A. A. Wilkins, and L. A. Morici, “Recent advances in the pursuit of an effective acinetobacter baumannii vaccine,” Pathogens, vol. 9, no. 12, pp. 1–19, 2020, doi: 10.3390/pathogens9121066.

N. Shirmohammadlou, H. Zeighami, F. Haghi, and M. Kashefieh, “Resistance pattern and distribution of carbapenemase and antiseptic resistance genes among multidrug-resistant acinetobacter baumannii isolated from intensive care unit patients,” J. Med. Microbiol., vol. 67, no. 10, pp. 1467–1473, 2018, doi: 10.1099/jmm.0.000826.

M. Safari, M. Saidijam, A. Bahador, R. Jafari, and M. Y. Alikhani, “High prevalence of multidrug resistance and metallo-beta-lactamase (mβl) producing acinetobacter baumanniiisolated from patients in icu wards, Hamadan, Iran,” J. Res. Health Sci., vol. 13, no. 2, pp. 162–167, 2013, doi: 10.34172/jrhs13896.

K. K. Ghaima, “Study OXA beta-lactamase Genes in Clinical Isolates of Multidrug Resistant Acinetobacter baumannii,” pp. 1–215, 2016.

A. I. Bagudo, G. A. Obande, A. Harun, K. Kaur, and B. Singh, “Advances in automated techniques to identify baumannii complex,” vol. 14, no. 5, pp. 177–186, 2020, doi: 10.1515/abm-2020-0026.

Z. Sadiq and A. Sehlawi, “Isolation and Identification of Acinetobacter baumannii Clinical Isolates using Novel Methods,” J. Babylon Univ., vol. 22, no. 3, pp. 1041–1050, 2014.

R. M. Abdullah, R. Zaid, and T. Ahmed, “2 nd International Scientific Conference of Applied Biotechnology,” J. Biotechnol. Res. Cent., vol. 13, no. 1, pp. 9–14, 2019.

L. Hall-Stoodley, J. W. Costerton, and P. Stoodley, “Bacterial biofilms: From the natural environment to infectious diseases,” Nat. Rev. Microbiol., vol. 2, no. 2, pp. 95–108, 2004, doi: 10.1038/nrmicro821.

K. K. Ghaima, M. K. S. Saadedin, and A. k Jassim, “Isolation, molecular identification and antimicrobial susceptibility of Acinetobacter baumannii isolated from Baghdad hospitals,” Int. J. Sci. Res. Publ., vol. 6, no. 5, p. 351, 2016, [Online]. Available: www.ijsrp.org.

S. A. Al-taliby and W. A. H. Al-daraghi, “Study of Antibiotic Resistance of Acinetobacter baumannii in Intensive Care Units ( I . C . Us ) and Burn Patients,” Iraqi J. Biotechnol., vol. 18, no. 1, pp. 32–36, 2019.

N. H. AL-Saleem, “Genotyping Relatedness of Acinetobacter baumannii isolated from Medical City/Baghdad.,” Baghdad University, 2013.

E. Babapour, A. Haddadi, R. Mirnejad, S. A. Angaji, and N. Amirmozafari, “Biofilm formation in clinical isolates of nosocomial Acinetobacter baumannii and its relationship with multidrug resistance,” Asian Pac. J. Trop. Biomed., vol. 6, no. 6, pp. 528–533, 2016, doi: 10.1016/j.apjtb.2016.04.006.